GET DAILY SIGNALSWhy Is AVITA Medical (RCEL) Stock Up +7.91% Today?
Key Takeaways
- RCEL shares climbed 7.91% to $16.92, up from the prior session's close of $15.68.
- The move is an earnings-driven rally following third-quarter results that beat estimates on both revenue and earnings per share.
- Management raised its full-year 2026 revenue guidance for the second consecutive quarter.
- Investors also responded to the removal of the company's going-concern qualification and a sharp reduction in quarterly cash burn.
- Traders are watching whether the stock holds above its prior 52-week high and whether fourth-quarter revenue guidance is achieved.
- Explore detailed Price Targets, Earnings data, and Forecast pages for a deeper look at the ticker's outlook.
- Discover the strongest-performing automated strategies in the current market via Trending AI Robots.
Opening Summary
RCEL — AVITA Medical, Inc., a Valencia, California-based therapeutic acute wound care company best known for its RECELL autologous cell harvesting system — surged 7.91% in Thursday's trading session. The stock climbed to $16.92, adding $1.24 from the prior close of $15.68. The rally extends a powerful run for the medical-device name, which has gained well over 300% in the past year. Markets attributed the advance to a stronger-than-expected third-quarter earnings report and an upward revision to full-year revenue guidance announced after Wednesday's close.
Earnings Results and Raised Guidance
The primary catalyst was AVITA Medical's third-quarter financial report. The company posted revenue of $26.11 million, a 53% increase from $17.1 million a year earlier and about 20% higher than the second quarter, topping the consensus estimate of roughly $22.35 million. The net loss narrowed to $0.20 per share, beating analyst expectations of a $0.24 loss. U.S. RECELL revenue reached $22.4 million, with unit volume rising approximately 21% sequentially to 3,196, while the newer Cohealyx dermal matrix grew about 21% to $2.1 million.
Just as important to investors, management raised its full-year 2026 revenue guidance to a range of $92 million to $94 million, up from the prior $86 million to $89 million forecast. This marked the second consecutive quarterly increase in guidance. The company also reaffirmed its expectation of reaching cash flow breakeven in the fourth quarter of 2026.
Improved Financial Position and Going-Concern Removal
The earnings release carried additional signals of financial strengthening. Net cash use fell to roughly $0.6 million in the quarter, down sharply from $3.2 million in the second quarter. Gross margin improved to 84.0%, from 81.3% a year earlier, aided by a RECELL-specific gross margin of 88.4%. The company also met the trailing twelve-month revenue milestone required to access the remaining $10 million tranche of its credit facility, which it drew down after quarter-end to reinforce liquidity.
Perhaps most notably, AVITA Medical announced that the "going concern" qualification had been removed from its quarterly filing, with management concluding that substantial doubt about its ability to continue as a going concern had been resolved. For a small-cap growth company that had faced existential questions, this reassurance removed a significant overhang and contributed meaningfully to the positive market reaction.
Regulatory and Reimbursement Tailwind
Adding support to the bullish narrative, the company separately disclosed that the Centers for Medicare & Medicaid Services finalized a national physician payment framework and simplified billing codes for RECELL procedures effective January 1, 2027. The new structure establishes national relative value units and replaces regional pricing, potentially easing adoption friction and improving reimbursement clarity for physicians using the device. This regulatory development reinforced the company's longer-term growth story alongside the quarterly beat.
Market Context and Trading Activity
The stock's move pushed it to a fresh 52-week high, eclipsing the prior peak of $16.90 set in late October. The rally follows several sessions of elevated trading activity, with daily volumes running above the company's typical average. The advance reflects a company-specific, earnings-driven move rather than broad sector momentum, as RCEL has outperformed both its small-cap medical-device peers and the broader market substantially over the trailing twelve months. Technical traders are now watching whether the shares can hold above the former high, which would convert prior resistance into a potential support level.
What Comes Next for RCEL
Investor attention now shifts to execution. The raised full-year guidance implies fourth-quarter revenue of approximately $24.9 million to $26.9 million, roughly flat with the third quarter at the midpoint — a point analysts flagged as a potential test of the stock's momentum after its dramatic run-up. Key watch items include the complete six-month Cohealyx dataset expected this month, continued adoption of RECELL and Cohealyx across hospital accounts, the transition to the new CMS billing framework in 2027, and the company's progress toward cash flow breakeven. Risks include margin dilution from lower-margin product lines, seasonally higher cash use in early 2027, and the potential for profit-taking after a triple-digit annual gain.
Trending AI Robots
Tickeron offers hundreds of AI-powered trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in the curated Trending AI Robots section. These automated strategies vary by approach, timeframe, performance metrics, and traded symbols, giving traders a range of options to explore. Whether you follow momentum names like RCEL or broader market trends, the page provides a convenient way to review the bots currently delivering standout results. Visit Trending AI Robots to learn more.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
RCEL in downward trend: price expected to drop as it breaks its higher Bollinger Band on October 21, 2026
RCEL broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 43 similar instances where the stock broke above the upper band. In 38 of the 43 cases the stock fell afterwards. This puts the odds of success at 88%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for RCEL moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 24 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 77%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 42 of 55 cases where RCEL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 76%.
The Moving Average Convergence Divergence Histogram (MACD) for RCEL turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 41 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RCEL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on RCEL as a result. In 79 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
Following a +3.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where RCEL advanced for three days, in 218 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 153 of 176 cases where RCEL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: RCEL's P/B Ratio (-17.420) is slightly lower than the industry average of (4.115). P/E Ratio (-10.889) is within average values for comparable stocks, (1.586). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (4.136) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. RCEL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RCEL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in the development and distribution of regenerative and respiratory medicine and treatments
Industry MedicalNursingServices
Advertisement